Ethical and legal issues in genetic epidemiology

Epidemiologic Reviews

Volumn 19, Issue 1, 1997, Pages 163-174

  Holtzman, Neil A ^a   Andrews, Lori B ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHICAGO KENT COLLEGE OF LAW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BREAST CANCER; CLINICAL PRACTICE; COMMERCIAL PHENOMENA; CONFIDENTIALITY; DIAGNOSTIC ACCURACY; DOCTOR PATIENT RELATION; ETHICS; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC SCREENING; HEMOCHROMATOSIS; HUMAN; INFORMED CONSENT; LEGAL ASPECT; MEDICAL RESEARCH; PENETRANCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY CONTROL; REVIEW; SOCIAL ASPECT;

EID: 0030697945     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017939     Document Type: Review

References (107)

1. Botstein D, White RL, Skolnick M, et al. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet 1980;32:314-31.
2. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037-48.
3. Murphy TF, Lappé MA, eds. Justice and the Human Genome Project. Berkeley, CA: University of California Press, 1994.
4. Annas GJ, Elias S. Gene mapping: using law and ethics as guides. New York, NY: Oxford University Press, 1992.
5. Kevles DJ, Hood L. The code of codes: scientific and social issues in the Human Genome Project. Cambridge, MA: Harvard University Press, 1992:1-363.
6. Suzuki D, Knudtson P. Genetics - the ethics of engineering life. Cambridge, MA: Harvard University Press, 1990:1-358.
7. Coughlin SS, Beauchamp TL. Ethics and epidemiology. New York, NY: Oxford University Press, 1996.
8. Gould SJ. The mismeasure of man. New York, NY: Norton, 1981.
9. Reilly P. The surgical solution: a history of involuntary sterilization in the United States. Baltimore, MD: Johns Hopkins University Press, 1991.
10. Kevles, DJ. In the name of eugenics: genetics and the use of human heredity. New York, NY: Knopf, 1985.
11. Andrews LB. Medical genetics: a legal frontier. Chicago, IL: American Bar Foundation, 1987.
12. Glass KC, Weijer C, Palmour RM, et al. Structuring the review of human genetics protocols: gene localization and identification studies. IRB 1996;18:1-9.
13. Penslar RL. Protecting human research subjects. Institutional Review Board guidebook. US National Institutes of Health, Office of Protection from Research Risks. Washington, DC: US GPO, 1993.
14. Juengst ET. The perils of genetic genealogy. CenterViews (Center for Biomedical Ethics, Case-Western Reserve University School of Medicine, Cleveland, OH) 1996;10:1-5.
15. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993;269:1970-4.
16. Earley CL, Strong LC. Certificates of confidentiality: a valuable tool for protecting genetic data. Am J Hum Genet 1995;57:727-31.
17. Annas GJ, Glantz LH, Roche PA. Drafting the Genetic Privacy Act: science, policy, and practical considerations. J Law Med Ethics 1995;23:360-6.
18. Clayton EW, Steinberg KK, Khoury MJ, et al. Informed consent for genetic research on stored tissue samples. JAMA 1995;274:1786-92.
19. ASHG report: statement on informed consent for genetic research. The American Society of Human Genetics. Am J Hum Genet 1996;59:471-4.
20. Weir RF, Horton JR. DNA banking and informed consent - Part 1. IRB 1995;17(4):1-4.
21. Weir RF, Horton JR. DNA banking and informed consent - Part 2. IRB 1995;17(5-6):1-8.
22. McEwen JE, Reilly PR. A review of state legislation on DNA forensic data banking. Am J Hum Genet 1994;54:941-58.
23. McGoodwin W. Genie out of the bottle. Genetic testing and the discrimination it's creating. Washington, DC: The Washington Post, May 5, 1996, p. G3.
24. McEwen JE, Reilly PR. A survey of DNA diagnostic laboratories regarding DNA banking. Am J Hum Genet 1995;56: 1477-86.
25. Grody WW. Molecular pathology, informed consent, and the paraffin block. (News). Diagn Mol Pathol 1995;4:155-7.
26. Wilmut I, Schnieke AE, McWhir J, et al. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385:810-13.
27. Moore v. Regents of the University of California. 1990;51 Cal. 3d 120, 271 Cal. Rptr. 146, 793 P.2d 479.
28. Susser M, Susser E. Choosing a future for epidemiology. I. Eras and paradigms. Am J Public Health 1996;86:668-73.
29. Winkelstein W Jr. Eras, paradigms, and the future of epidemiology. (Editorial). Am J Public Health 1996;86:621-2.
30. Pearce N. Traditional epidemiology, modern epidemiology, and public health. Am J Public Health 1996;86:678-83.
31. Watt DC, Lindenbaum RH, Jonasson JA, et al. Probes in Huntington's chorea. (Letter). Nature 1986;320:21.
32. Gusella JF. Probes in Huntington's chorea. (Reply to Letter). Nature 1986;320:21-22.
33. Risch N, Botstein D. A manic depressive history. Nat Genet 1996;12:351-3.
34. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-7.
35. Rebbeck TR, Couch FJ, Kant J, et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 1996;59:547-53.
36. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995;332:861-7.
37. Cutting GR. Cystic fibrosis. In: Rimoin DL, Connor JM, Pyeritz RE, eds. Emery and Rimoin's principles and practice of medical genetics. 3rd ed. London, England: Churchill Livingstone. 1996;2685-717.
38. Statement from the National Institutes of Health Workshop on Population Screening for the Cystic Fbrosis Gene. N Engl J Med 1990;323:70-1.
39. Caskey CT, Kaback MM, Beaudet AL. The American Society of Human Genetics statement on cystic fibrosis screening. Am J Hum Genet 1990;46:393.
40. Marshall E. ELSI's cystic fibrosis experiment. Science 1996; 274:489.
41. Consensus development statement: genetic testing for cystic fibrosis. Bethesda, MD: US National Institutes of Health, 1997.
42. Hanson MF, Cavenee WK. Genetics of cancer predisposition. Cancer Res 1987;47:5518-27.
43. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
44. Knudson AG. All in the (cancer) family. (News). Nat Genet 1993;5:103-4.
45. Smith HS, Lu Y, Deng G, et al. Molecular aspects of early stages of breast cancer progression. J Cell Biochem Suppl 1993;17G:144-52.
46. Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (< or = 60 years) with coronary artery disease. Am J Cardiol 1993;71: 631-9.
47. Matsuda I, Matsuura T, Nishiyori A, et al. Phenotypic variability in male patients carrying the mutant ornithine transcarbamylase (OTC) allele, Arg40His, ranging from a child with an unfavourable prognosis to an asymptomatic older adult. J Med Genet 1996;33:645-8.
48. Schatzkin A, Goldstein A, Freedman LS. What does it mean to be a cancer gene carrier? Problems in establishing causality from the molecular genetics of cancer. J Natl Cancer Inst 1995;87:1126-30.
49. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
50. FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143-9.
51. Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996;347:1643-5.
52. Schulman JD, Stern HJ. Genetic predisposition testing for breast cancer. Cancer J Sei Am 1996;2:244-9.
53. Hubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med 1996;334:1192-3.
54. Burke W, Kahn MJE, Garber JE, et al. "First Do No Harm" applies to cancer susceptibility testing too. Cancer J Sci Am 1996;2:250-2.
55. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336: 1401-8.
56. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
57. Roa BB, Boyd AA, Volcik K, et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
58. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174deIT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-90.
59. Holtzman NA. Benefits and risks of emerging genetic technologies: the need for regulation. Clin Chem 1994;40: 1652-7.
60. Seshadri S, Drachman DA, Lippa CE. Apolipoprotein E ∈4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol 1995;52:1074-9.
61. Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group. Lancet 1996;347:1091-5.
62. ACMG statement: statement on storage and use of genetic materials. American College of Medical Genetics Storage of Genetic Materials Committee. Am J Hum Genet 1995;57: 1499-500.
63. Mayeux R, Schupf N. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Am J Public Health 1995;85:1280-4.
64. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nal Genet 1996;13:399-408.
65. Holtzman NA. Proceed with caution: predicting genetic risks in the recombinant DNA era. Baltimore, MD: Johns Hopkins University Press, 1989.
66. Holtzman NA. What drives neonatal screening programs? (Editorial). N Engl J Med 1991;325:802-4.
67. Farrell PM, Mischler EH. Newborn screening for cystic fibrosis. The Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr 1992;39:35-70.
68. Kerlikowske K, Grady D, Barclay J, et al. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276:33-8.
69. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
70. Holtzman NA. Testing for genetic susceptibility to common cancers: clinical and ethical issues. Adv Oncol 1997;13: 9-15.
71. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. JAMA 1995;274:1627-9.
72. Statement of The American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1994;55:i-iv.
73. US Food and Drug Administration. Medical devices; classification/reclassification; restricted devices; analyte specific reagents. Federal Register 1996;61:10484-9.
74. Andrews LB, Fullarton JE, Holtzman NA, et al., eds. Assessing genetic risks: implications for health and social policy. Washington DC: National Academy Press, 1994.
75. Promoting safe and effective genetic testing in the United States. Task Force on Genetic Testing. Bethesda, MD: US National Institutes of Health (in press).
76. Killer EH, Landenburger G, Natowicz MR. Public participation in medical policy making and the status of consumer autonomy: the example of newborn screening programs in the United States. Am J Public Health (in press).
77. Andrews LB. State laws and regulations governing newborn screening. Chicago, IL: American Bar Foundation, 1985.
78. Meaney FJ, Kinney S, Kling S, et al. Assessing genetic risks - implications for heatlh and social policy. Response from the Newborn Screening Committee of the Council of Regional Networks for Genetic Services. Screening 1996;4: 247-9.
79. Faden R, Chwalow AJ, Holtzman NA, et al. A survey to evaluate parental consent as public policy for neonatal screening. Am J Public Health 1982;72:1347-52.
80. Holtzman NA, Faden R, Chwalow AJ, et al. Effect of informed parental consent on mothers' knowledge of newborn screening. Pediatrics 1983;72:807-12.
81. Stamatoyannopoulos G. Problems of screening and counseling in the hemoglobinopathies. In: Motulsky AG, Ebling FJG, eds. Birth defects: proceedings of the fourth international conference, Vienna, Austria, 2-8 September 1973. Amsterdam, The Netherlands: Excerpta Medica, 1974: 268-76.
82. Wald NJ. Couple screening for cystic fibrosis. Lancet 1991; 338:1318-19.
83. Rosner F. Confidential Tay-Sachs carrier screening. (Letter). N Y State J Med 1989;89:585.
84. Tambor ES, Bernhardt BA, Chase GA, et al. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 1994;55: 626-37.
85. Chase GA, Bernhardt BA, Faden RR, et al. Confirmation of a finding on tolerance for test uncertainty (TTU) in cystic fibrosis carrier screening. (Abstract). Am J Hum Genet 1995; 57:A29.
86. Wadman M. Women need not apply. The DNA test that doctors don't want to share. Washington, DC: The Washington Post, May 5, 1996, p. C3.
87. Geller G, Bernhardt BA, Helzlsouer K, et al. Informed consent and BRCA1 testing. (Letter). Nat Genet 1995;11:364.
88. Holtzman NA, Bernhardt BA, Doksum T, et al. Education about BRCA1 testing decreases women's interest in being tested. (Abstract). Am J Hum Genet 1996;59:A56.
89. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 1996; 275:1885-92.
90. Billings PR, Kohn MA, de Cuevas M, et al. Discrimination as a consequence of genetic testing. Am J Hum Genet 1992; 50:476-82.
91. Geller LN, Alper JS, Billings PR, et al. Individual, family, and societal dimensions of genetic discrimination: a case study analysis. Sci Eng Ethics 1996;2:71-88.
92. Lapham EV, Kozma C, Weiss JO. Genetic discrimination: perspectives of consumers. Science 1996;274:621-4.
93. Genetic monitoring and screening in the workplace. US Congress Office of Technology Assessment. Washington DC: US GPO, 1990.
94. Rothenberg KH. Genetic information and health insurance: state legislative approaches. J Law Med Ethics 1995;23: 312-19.
95. 104th Congress. Public Law 104-191. 1996; 110 Stat. 1936-1947.
96. Holtzman NA. Medical and ethical issues in genetic screening-an academic view. Environ Health Perspect 1996;104(Suppl 5):987-90.
97. Wertz DC, Fanos JH, Reilly PR. Genetic testing for children and adolescents: who decides? JAMA 1994;272:875-81.
98. The genetic testing of children. Working Party of the Clinical Genetics Society (UK). J Med Genet 1994;31:785-97.
99. Pelias MZ. Duty to disclose in medical genetics: a legal perspective. Am J Med Genet 1991;39:347-54.
100. Harper PS, Clarke A. Should we test children for "adult" genetic diseases? Lancet 1990;335:1205-6.
101. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet 1995;57:1233-41.
102. Susser M, Susser E. Choosing a future for epidemiology. II. From black box to Chinese boxes and eco-epidemiology. Am J Public Health 1996;86:674-7.
103. Holtzman NA. Testing for genetic susceptibility: what you see is not what you get. Accountability Res 1996;5:95-101.
104. Nelkin D, Lindee MS. The DNA mystique: the gene as a cultural icon. New York, NY: Freeman, 1995.
105. Trichopoulos D, Li FP, Hunter DJ. What causes cancer? Sci Am 1996;275:80-7.
106. Weinberg RA. How cancer arises. Sci Am 1996;275:62-70.
107. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996;88:496-509.